Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Fortrea Holdings Inc. (FTRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: FTRE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $9.53
1 Year Target Price $9.53
| 0 | Strong Buy |
| 1 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.2% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 880.76M USD | Price to earnings Ratio - | 1Y Target Price 9.53 |
Price to earnings Ratio - | 1Y Target Price 9.53 | ||
Volume (30-day avg) 12 | Beta 1.85 | 52 Weeks Range 3.97 - 25.28 | Updated Date 11/5/2025 |
52 Weeks Range 3.97 - 25.28 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.57% | Operating Margin (TTM) -1.54% |
Management Effectiveness
Return on Assets (TTM) -1.42% | Return on Equity (TTM) -100.49% |
Valuation
Trailing PE - | Forward PE 6.12 | Enterprise Value 2031480000 | Price to Sales(TTM) 0.32 |
Enterprise Value 2031480000 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.74 | Enterprise Value to EBITDA 92.35 | Shares Outstanding 90800000 | Shares Floating 83878316 |
Shares Outstanding 90800000 | Shares Floating 83878316 | ||
Percent Insiders 0.52 | Percent Institutions 110.72 |
Upturn AI SWOT
Fortrea Holdings Inc.
Company Overview
History and Background
Fortrea Holdings Inc. was spun off from Labcorp (LH) in July 2023. It focuses on providing clinical trial and drug development services.
Core Business Areas
- Clinical Development Services: Provides Phase I-IV clinical trial management, data management, biostatistics, and medical writing services to pharmaceutical, biotechnology, and medical device companies.
- Drug Development Solutions: Offers comprehensive solutions for drug safety, regulatory affairs, market access, and strategic consulting.
Leadership and Structure
Fortrea is led by CEO Thomas Pike. The company operates with a functional structure, organized around its key service offerings.
Top Products and Market Share
Key Offerings
- Phase I-IV Clinical Trials: Management and execution of clinical trials across all phases. Market share is difficult to pinpoint precisely due to fragmented market, but Fortrea competes with large CROs. Competitors: IQVIA, ICON, PPD (Thermo Fisher Scientific), Syneos Health.
- Drug Safety and Pharmacovigilance: Services related to monitoring and reporting adverse events and ensuring drug safety. Competitors: IQVIA, Genpact, Accenture Life Sciences.
- Regulatory Consulting: Assistance with regulatory submissions and approvals. Competitors: Parexel, ICON, Charles River Laboratories.
Market Dynamics
Industry Overview
The Clinical Research Organization (CRO) market is experiencing significant growth, driven by increasing R&D spending in the pharmaceutical and biotechnology industries, the rise of personalized medicine, and the growing complexity of clinical trials.
Positioning
Fortrea is a mid-sized CRO, positioned to capitalize on the growing demand for outsourced clinical trial services. Its strengths lie in its experience and global reach.
Total Addressable Market (TAM)
The global CRO market is estimated to be worth hundreds of billions of dollars. Fortrea is positioned to capture a significant portion of this TAM, estimated in 2024 at around $90 billion, by focusing on specific therapeutic areas and offering tailored solutions to its clients.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Comprehensive service offerings
- Global reach
- Strong client relationships
- Focused on clinical trials and drug development
Weaknesses
- Relatively new company as a spin-off
- High dependence on pharmaceutical and biotechnology R&D spending
- Integration risks associated with spin-off
- Potential for pricing pressure in the CRO market
Opportunities
- Growing demand for outsourced clinical trial services
- Expansion into emerging markets
- Adoption of new technologies such as AI and machine learning
- Strategic acquisitions to expand service offerings
Threats
- Competition from larger CROs
- Economic downturn affecting pharmaceutical R&D spending
- Changes in regulatory requirements
- Loss of key clients
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- ICON (ICLR)
- Thermo Fisher Scientific (TMO)
- Syneos Health (SYNH)
Competitive Landscape
Fortrea faces intense competition from larger, more established CROs. Its advantages include its focused expertise and smaller size, which allows for greater flexibility and responsiveness.
Growth Trajectory and Initiatives
Historical Growth: Limited historical data due to the recent spin-off.
Future Projections: Future growth is expected to be driven by the increasing demand for outsourced clinical trial services. Analyst estimates vary, but project revenue growth.
Recent Initiatives: Focus on cost optimization, strategic partnerships, and expansion into new therapeutic areas.
Summary
Fortrea is a relatively new company spun off from Labcorp, operating in the growing CRO market. While it benefits from the industry's tailwinds, it faces competition from larger players and integration challenges. Its success depends on its ability to execute its growth strategy and maintain strong client relationships. Monitoring its financial performance and strategic initiatives is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and based on available estimates. Investing in stocks involves risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortrea Holdings Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2023-07-03 | CEO & Director Mr. Anshul Thakral | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14500 | Website https://www.fortrea.com |
Full time employees 14500 | Website https://www.fortrea.com | ||
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.